Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 4,178
Out of 5,241 analysts
79
Total ratings
30.56%
Success rate
-20.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $147 → $171 | $145.66 | +17.40% | 6 | Apr 22, 2026 | |
| REPL Replimune Group | Downgrades: Market Perform | $11 → $2 | $5.22 | -61.69% | 12 | Apr 13, 2026 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $20.59 | +264.25% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $26.54 | +1.73% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $28.05 | +163.81% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $51.50 | -78.64% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $17.58 | +190.10% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.67 | +877.84% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $4.45 | +1,023.60% | 4 | Aug 22, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $4.25 | +182.35% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $10.87 | +139.19% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $9.22 | +203.69% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $11.22 | +372.37% | 7 | Aug 5, 2021 |
Revolution Medicines
Apr 22, 2026
Maintains: Outperform
Price Target: $147 → $171
Current: $145.66
Upside: +17.40%
Replimune Group
Apr 13, 2026
Downgrades: Market Perform
Price Target: $11 → $2
Current: $5.22
Upside: -61.69%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $20.59
Upside: +264.25%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $26.54
Upside: +1.73%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $28.05
Upside: +163.81%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $51.50
Upside: -78.64%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $17.58
Upside: +190.10%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.67
Upside: +877.84%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.45
Upside: +1,023.60%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $4.25
Upside: +182.35%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $10.87
Upside: +139.19%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $9.22
Upside: +203.69%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $11.22
Upside: +372.37%